As part of our Triple Bottom Line business model, we are committed to making a difference by supporting scientific and humanitarian causes that positively impact people’s lives.
Novo Nordisk has been a longtime supporter of the Billie Jean King WTT Charities as the sponsor of the Novo Nordisk Donnelly Awards. Two $7,500 national awards are granted to students aged 14-21 who have diabetes and play tennis competitively. Eight regional awards of $3,000 each will also be granted. Winners of the two national awards will be presented their awards by Billie Jean King in 2018. Applications must be received by April 1, 2018. To download an application, go to www.wtt.com and click on Novo Nordisk Donnelly Awards. Email completed application to email@example.com.
Novo Nordisk is proud to support educational programs that encourage healthy living and increase disease awareness, prevention, optimal treatment, and management in therapeutic areas of interest. Each year, we provide funding to hundreds of independent educational grants that provide continuing education to practicing health care professionals and those in training, as well as members of the community, patients, and their caregivers.
Novo Nordisk supports new initiatives that help address health disparities and improve access to care among the Native American community, which includes many people who are affected disproportionately by diabetes.
The Native American Health Initiative was developed in 2010 and born from the passion, dedication, and personal experience of our employees. The goal of the program is to replace the current culture of diabetes with one of prevention, management, and improved care. Our inaugural project is a partnership with the Rosebud Lakota Sioux Tribe, which is located in a remote area of South Dakota.
After completing a four-month assessment conducted by The International Diabetes Center (IDC), which looked at the challenges, barriers to care, and limited existing resources for diabetes education and prevention currently available to residents of Rosebud, the Rosebud Tribal Council and Novo Nordisk agreed to implement the following to improve diabetes outcomes:
We understand the importance of independence for people living with diabetes. In an effort to improve the everyday lives of patients and increase quality of life, we support Canine Partners for Life an organization dedicated to training service dogs.
At Canine Partners for Life, diabetes alert dogs are trained to sense blood sugar level changes in their human partner. Although this canine partner is not a replacement for regular self-testing or medical intervention, he/she helps those who face challenges living with diabetes better predict their blood sugar levels. The dog gives preemptive alerts allowing their partner to be able to take precautions to avoid potentially life-threatening conditions.
Our support has provided Canine Partners for Life with time and resources to properly conduct research and develop an effective training module for diabetes alert dogs. The company has supported Canine Partners for Life since 2008, sponsoring five diabetes alert dogs and giving more than $250,000 for training and research. Novo Nordisk continues its support in an effort to make substantial changes and inroads in improving the quality of life for people living with diabetes.
We proudly support the Stop Diabetes movement as the National Premier Sponsor and Red Strider Sponsor of the American Diabetes Association's signature fundraising event, Step Out: Walk to Stop Diabetes.
Step Out Walks take place in more than 140 cities around the country to raise awareness about diabetes and to support fundraising activities, which help to change the future of this growing epidemic. Each year, thousands of Novo Nordisk employees and their families volunteer their time to form teams and raise funds for and awareness of this important cause.
Novo Nordisk has provided $7.5 million to support the American Diabetes Association’s program, Pathway to Stop Diabetes, which aims to inspire and support the next generation of diabetes researchers. Despite the disease’s epidemic proportions, research is still critically underfunded. Although researchers have made significant strides against the disease, continued progress depends on adequate funding. With a goal of funding 100 new diabetes investigators over the next decade, Pathway provides crucial support to researchers focusing on innovative ideas and transformational approaches. We believe that each new discovery brings us one step closer to finding a cure for diabetes and we have been a leading corporate sponsor of the program since 2013.
For the past five years, Novo Nordisk has participated in the Hemophilia Camp Program. There are approximately 60 Hemophilia Camps in the US. In general, the goal of these camps is to provide children with bleeding disorders with a typical camp experience, where everybody is treated the same and where possibilities, not limitations, are stressed. Camp provides the opportunity for patients and families to connect and learn from one another. For many patients, camp is where essential life-skills such as self-infusion is learned.